Cellular Immunity in the Peritoneum

Adoptive Cell Transfer, Volume 371, highlights advances in the field, covering topics such as tumor microenvironment impact, dendritic cell transfer, CAR-T cell dysfunction, NK cell-based cancer immunotherapy, and improving adoptive T-cell therapy with cytokines administration.

Format: Hardback
Length: 144 pages
Publication date: 01 August 2022
Publisher: Elsevier Science & Technology

Adoptive Cell Transfer,Volume 371 in the International Review of Cell and Molecular Biology series highlights advances in the field, with this new volume presenting interesting chapters written by an international board of authors who expound on topics such as the Impact of tumor microenvironment on Adoptive Cell Transfer activity, Dendritic Cell Transfer, CAR-T Cell dysfunction and exhaustion, NK Cell-based cancer immunotherapy, Enabling CAR-T cells for solid tumors: rage against the suppressive tumor microenvironment, Improving Adoptive T-Cell therapy with cytokines administration, and What will (and should) be improved in Immunotherapy with CAR?

The tumor microenvironment (TME) is a complex and dynamic environment that plays a critical role in regulating the activity of adoptive cell transfer (ACT) therapies. The TME consists of a variety of cells, including immune cells, stromal cells, and tumor cells, that interact with each other to promote or suppress tumor growth and metastasis.

One of the key ways in which the TME influences ACT is through the expression of immune checkpoint molecules. Immune checkpoint molecules are proteins that bind to immune cells and inhibit their ability to attack tumor cells. Examples of immune checkpoint molecules include PD-1, PD-L1, and CTLA-4.

The TME can also influence the activity of ACT therapies through the expression of other molecules that promote tumor growth and metastasis. For example, tumor cells can express molecules that stimulate the growth of blood vessels, which can help tumors to grow and spread to other parts of the body. Stromal cells can also express molecules that promote tumor growth and metastasis, such as VEGF and EGF.

The TME can also influence the activity of ACT therapies through the recruitment of immune cells to the tumor site. For example, tumor cells can express molecules that attract immune cells, such as CD40 and CD86. Immune cells can then infiltrate the tumor site and attack tumor cells.

There are several ways in which the TME can be manipulated to improve the activity of ACT therapies. One approach is to use drugs that block the expression of immune checkpoint molecules. These drugs can help to restore the immune response against tumor cells and improve the activity of ACT therapies.

Another approach is to use drugs that target other molecules that promote tumor growth and metastasis. These drugs can help to reduce the growth and spread of tumors and improve the activity of ACT therapies.

Finally, it is important to understand the role of the TME in the development and progression of cancer. By understanding the TME, researchers can develop new therapies that target specific aspects of the TME and improve the treatment of cancer.

In conclusion, the tumor microenvironment is a complex and dynamic environment that plays a critical role in regulating the activity of adoptive cell transfer therapies. By understanding the TME and manipulating it to improve the activity of ACT therapies, researchers can develop new and effective treatments for cancer.

Dendritic Cell Transfer (DCT) is a promising immunotherapy approach for the treatment of cancer. DCT involves the transfer of dendritic cells (DCs), which are immune cells that play a critical role in the immune response against cancer.

One of the key advantages of DCT is that it can activate the immune system against cancer cells. DCs are able to present antigens to other immune cells, which can then trigger an immune response against the cancer cells. DCT can also stimulate the production of cytokines, which are proteins that play a critical role in the immune response against cancer.

There are several different types of DCT, including autologous DCT, allogeneic DCT, and syngeneic DCT. Autologous DCT involves the transfer of DCs that are derived from the patient's own body. Allogeneic DCT involves the transfer of DCs that are derived from a donor's body. Syngeneic DCT involves the transfer of DCs that are derived from the patient's own tumor cells.

One of the challenges of DCT is the development of effective protocols for the transfer of DCs. There are several different methods for the transfer of DCs, including intravenous injection, intradermal injection, and subcutaneous injection. The method of transfer may depend on the type of cancer and the location of the tumor.

Another challenge of DCT is the development of effective protocols for the activation of DCs. There are several different methods for the activation of DCs, including the use of cytokines, Toll-like receptor agonists, and other agents. The method of activation may depend on the type of cancer and the location of the tumor.

There are several different types of cancer that can be treated with DCT, including leukemia, lymphoma, and melanoma. DCT has been shown to be effective in treating these types of cancer, and there is ongoing research to explore the use of DCT in other types of cancer.

In conclusion, Dendritic Cell Transfer (DCT) is a promising immunotherapy approach for the treatment of cancer. DCT involves the transfer of dendritic cells, which are immune cells that play a critical role in the immune response against cancer. DCT can activate the immune system against cancer cells and stimulate the production of cytokines. There are several different types of DCT, including autologous DCT, allogeneic DCT, and syngeneic DCT. The development of effective protocols for the transfer of DCs and the activation of DCs is a challenge, but ongoing research is exploring the use of DCT in other types of cancer.

Weight: 450g
Dimension: 229 x 152 (mm)
ISBN-13: 9780323994002